Australian Vaccine Technologies

Australian Vaccine Technologies (AVT) is an Australian biotechnology company specializing in the research and development of vaccine candidates for infectious diseases. The company gained international prominence for developing SpikoGen (also known as COVAX-19), a recombinant protein subunit vaccine targeting the SARS-CoV-2 spike protein. SpikoGen was developed in collaboration with the Iranian pharmaceutical company CinnaGen and received emergency use authorization in Iran, marking it as one of the first Australian-designed COVID-19 vaccines to reach the market. AVT utilizes the proprietary Advax adjuvant technology to enhance the immune response of its vaccine candidates. The company continues to focus on addressing global health challenges through innovative immunization strategies and international research partnerships.